» Articles » PMID: 33090481

Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

Overview
Journal Headache
Publisher Wiley
Specialties Neurology
Psychiatry
Date 2020 Oct 22
PMID 33090481
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Migraine is typically divided into 2 headache frequency denominated categories, episodic migraine (EM) and chronic migraine (CM). Characterizing more narrow headache day frequency groups may be of value for better understanding the broad range of migraine experience and making treatment decisions.

Objective: To characterize the impact and burden of migraine in 4 monthly headache day (MHD) categories.

Methods: Respondents to the American Migraine Prevalence and Prevention Study 2005 survey who met criteria for migraine were categorized into low frequency episodic migraine (LFEM) 0-3, moderate frequency episodic migraine (MFEM) 4-7, high frequency episodic migraine (HFEM) 8-14, and CM with ≥15 headache days per month. Data including sociodemographics, headache features and symptomology, comorbidities, cutaneous allodynia, and severe migraine-related disability were compared among groups. We combined the low- and medium-frequency EM groups (L/MFEM) and compared them with the HFEM group in 1 set of models and compared the HFEM and CM groups in a second set of models. Binary logistic regression, linear regression, and ordered logistic regression were used depending upon the variable type and adjusted for sociodemographics.

Results: Among 11,603 eligible respondents with migraine, 67.7% (7860/11,603) were categorized with LFEM, 17.7% (2051/11,603) with MFEM, 7.8% (898/11,603) with HFEM, and 6.8% (794/11,603) with CM. The mean age was 46 (SD 13.7), 80.2% (9301/11,603) were female, and 90.0% (10,187/11,323) were White, 6.9% were Black (784/11,323), and 3.1% (352/11,323) were identified as Other race(s). Individuals with HFEM differed from L/MFEM on a wide range of sociodemographic variables in the categories of headache features, disability, and comorbidities while few differences were found when modeling HFEM vs CM. In comparison with L/MFEM and HFEM, the HFEM group was more likely to have severe disability (P < .001 OR = 1.74 [1.42, 2.15]), chronic pain (P ≤ .007 OR = 1.35 [1.09, 1.69]), arthritis (P = .001 OR = 1.44 [1.15, 1.80]), high cholesterol (P = .005, OR = 1.37 [1.10, 1.70]), ulcers (P = .016, OR = 1.44 [1.07, 1.93]), and depression (Patient Health Questionnaire [PHQ-9]) (P < .001 OR = 1.50 [1.22, 1.84]).

Conclusion: While rates of migraine symptoms, headache impact and disability, and comorbidities generally increased with increases in MHD frequency, respondents with HFEM and CM were remarkably similar on a broad range of variables including sociodemographics, disability/impact, and comorbidities. There were many more significant differences between the HFEM and L/MFEM groups on the same variables. Future work should use empirical strategies to identify naturally occurring groups and possibly reconsider the boundary between CM and HFEM.

Citing Articles

The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective.

Vikelis M, Kourlaba G, Barba L, Bilias K, Barbalia E, Solakidi A Front Neurol. 2025; 16:1558014.

PMID: 40066304 PMC: 11892325. DOI: 10.3389/fneur.2025.1558014.


Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.

Kourlaba G, Vikelis M, Karapanayiotides T, Solakidi A, Trafalis D, Lioliou K Front Neurol. 2025; 16:1556808.

PMID: 40040919 PMC: 11878100. DOI: 10.3389/fneur.2025.1556808.


Anxiety Disorders, Anxious Symptomology and Related Behaviors Associated With Migraine: A Narrative Review of Prevalence and Impact.

Raudenska J, Macko T, Vodickova S, Buse D, Javurkova A Curr Pain Headache Rep. 2025; 29(1):40.

PMID: 39878907 PMC: 11779792. DOI: 10.1007/s11916-024-01312-9.


Role of Psychological Factors in Migraine.

Yu X, Tan G Cureus. 2025; 16(12):e75858.

PMID: 39822418 PMC: 11736672. DOI: 10.7759/cureus.75858.


Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults.

Raja A, Asim R, Shuja M, Raja S, Muhammad T, Bajaj S Front Neurol. 2024; 15:1468961.

PMID: 39399876 PMC: 11466836. DOI: 10.3389/fneur.2024.1468961.